The awarded facility includes two manufacturing areas utilizing 6x1KL single-use bioreactors for perfusion and 12x4KL single-use bioreactors for fed-batch, making it one of the largest facilities of its kind in Europe. Construction of the 467,500-square-foot greenfield facility was started in December 2018 and operations began in December 2021, generating over 6,000 construction jobs and more than 500 highly skilled jobs for residents of the North-East region of Ireland. It took only nine months from the start of operations for the facility to receive its first GMP certificate from the Irish Health Products Regulatory Authority (HPRA). Following WuXi Biologics' Environmental, Social and Governance (ESG) strategy, sustainable concepts are adopted in the site construction and operations, including reducing energy use and recycling resources. Currently, 100% of power supply comes from renewable energy at Ireland site.

Dr. Chris Chen, CEO of WuXi Biologics, commented, "We are very proud to be recognized by ISPE for the second time. Receiving the FOYA award in the Operations category validates our Global Dual Sourcing strategy, leading technology platform, and excellent execution, and will motivate us to continue striving for the highest level of service to enable our global partners for the benefit of patients worldwide."

Brendan McGrath, Vice President and Head of WuXi Biologics Ireland Site, added, "This recognition by ISPE is a testament to our team's dedication and relentless pursuit of excellence. It also signifies success for our clients, partners and local community, and ultimately for the patients who rely on the life-saving biologics manufactured at our Ireland site."

In 2014, WuXi Biologics was awarded the FOYA Honorable Mention for its manufacturing facility in Wuxi city, China.